麦澜德限售股解禁市值超28亿，股东减持压力引关注

Core Viewpoint - A significant share lock-up release is set to occur on February 11, 2026, involving 63.17% of the total share capital, which may lead to increased supply and potential short-term stock price volatility [1][2]. Financial Performance - For the first three quarters of 2025, the company reported revenue of 344 million yuan, reflecting a year-on-year increase of 4.01% - The net profit attributable to shareholders was 96 million yuan, showing a slight decline of 0.07% year-on-year - The gross profit margin stood at 70.05%, and the debt ratio was 9.52%, indicating stable profitability but slowing growth [2]. Business Development - The company focuses on pelvic rehabilitation devices and is expanding into new areas such as reproductive anti-aging and brain-machine interfaces, which are viewed positively for long-term growth by institutions - Increased R&D investment, with a research expense ratio of 13.88% in Q3 2025, may suppress short-term profits [2]. Market Impact - The high percentage of shares being unlocked could lead to intensified selling pressure from original shareholders, potentially exacerbating stock price fluctuations - Historical data indicates a 17.23% increase in the number of shareholders post-lock-up, suggesting a widening market divergence - The A-share medical device sector has recently experienced volatility, with the sector's index showing no change on February 13, 2026, indicating that the stock may be influenced by overall market sentiment [3]. Liquidity Concerns - The liquidity impact of the lock-up release should not be overlooked, despite the company's technical advantages in its niche market [3].